A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Phase 3
868
about 12 years
18+
68 sites in AK, AZ, CA +26
About this study
This trial is testing a treatment with intismeran autogene and pembrolizumab compared to placebo plus pembrolizumab for people who have non-small cell lung cancer. The goal is to see if the combination of intismeran autogene and pembrolizumab improves disease-free survival.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Receive Intismeran autogene
- 3.Receive Pembrolizumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Disease- Free Survival (DFS)
Secondary: Change from Baseline in the EORTC QLQ-C30 Dyspnea (Item 8) Score on the EORTC QLQ-C30, Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30, Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30, Change from Baseline in the EORTC QLQ-LC24 Chest Pain (Item 40) Score on the EORTC QLQ-LC24, Change from Baseline in the EORTC QLQ-Lung Cancer Questionnaire (LC24) Coughing (Items 31 and 52) Combined Score on the EORTC QLQ-LC24, Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score, Distant Metastasis-Free Survival (DMFS), Number of Participants Who Discontinue Study Treatment Due to an AE
Oncology